|Day Low/High||1.21 / 1.26|
|52 Wk Low/High||1.06 / 2.12|
Data supports advanced PLX-PAD clinical studies including dosing regimen, systemic therapeutic effects and superiority of the cells over cytokines
Patent significantly expands potential indications for PLX-R18 and grants Pluristem broad coverage in the treatment of damaged hematopoietic systems
Pluristem's ARS program is developed and funded by the U.S. National Institutes of Health and the U.S. Department of Defense, and is in preparation for a pivotal study
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.